AAAAAA

   
Results: 1-25 | 26-45
Results: 1-25/45
TIMING OF COMBINED CHEMORADIOTHERAPY IN THE CONSERVATIVE TREATMENT OFLOCALLY ADVANCED BREAST-CANCER (LABC)
Authors: PIERGA JY CAMPANA F LAGUERRE B PALANGIE T FOURQUET A ASSELAIN B DIERAS V BEUZEBOC P DORVAL T SCHOLL S POUILLART P
Citation: Jy. Pierga et al., TIMING OF COMBINED CHEMORADIOTHERAPY IN THE CONSERVATIVE TREATMENT OFLOCALLY ADVANCED BREAST-CANCER (LABC), European journal of cancer, 34, 1998, pp. 42-42
THE IMMUNE-RESPONSE TO BREAST-CANCER
Authors: SCHOLL SM BARON C SALAMARO J BEUZEBOC P DENEUX L BEUVON F POUILLART P
Citation: Sm. Scholl et al., THE IMMUNE-RESPONSE TO BREAST-CANCER, European journal of cancer, 34, 1998, pp. 149-149
IS PRIMARY CHEMOTHERAPY USEFUL IN ALL PATIENTS
Authors: SCHOLL S BEUZEBOC P ASSELAIN B PIERGA JY POUILLART P
Citation: S. Scholl et al., IS PRIMARY CHEMOTHERAPY USEFUL IN ALL PATIENTS, European journal of cancer, 34, 1998, pp. 22-22
INITIAL VERSUS DELAYED RADIOTHERAPY COMBINED WITH CONTINUOUS 5-FLUOROURACILE (F), CYCLOPHOSPHAMIDE (C) AND DOXORUBICINE (A) IN INFLAMMATORYBREAST-CANCER (IBC)
Authors: PALANGIE T ASSELAIN B CAMPANA F BEUZEBOC P DIERAS V DORVAL T JOUVE M PIERGA JY SCHOLL S POUILLART P
Citation: T. Palangie et al., INITIAL VERSUS DELAYED RADIOTHERAPY COMBINED WITH CONTINUOUS 5-FLUOROURACILE (F), CYCLOPHOSPHAMIDE (C) AND DOXORUBICINE (A) IN INFLAMMATORYBREAST-CANCER (IBC), European journal of cancer, 34, 1998, pp. 64-64
PREDICTIVE FACTORS OF RESPONSE TO FIRST LINE CHEMOTHERAPY IN METASTATIC BREAST-CANCER (MBC)
Authors: ROBAIN M PIERGA JY LAURENCE V JOUVE M DIERAS V BEUZEBOC P PALANGIE T DORVAL T SCHOLL S EXTRA JM ASSELAIN B POUILLART P
Citation: M. Robain et al., PREDICTIVE FACTORS OF RESPONSE TO FIRST LINE CHEMOTHERAPY IN METASTATIC BREAST-CANCER (MBC), Annals of oncology, 9, 1998, pp. 71-71
PHASE-II STUDY OF TAXOL (PACLITAXEL) AND CARBOPLATIN IN PATIENTS WITHADVANCED TRANSITIONAL-CELL CARCINOMA OF THE UROTHELIUM (TCC)
Authors: MOTTET N PRAPOTNICH D BEUZEBOC P DIPALMA M BUI N EYMARD JC MERCAT A GARET F DROZ JP
Citation: N. Mottet et al., PHASE-II STUDY OF TAXOL (PACLITAXEL) AND CARBOPLATIN IN PATIENTS WITHADVANCED TRANSITIONAL-CELL CARCINOMA OF THE UROTHELIUM (TCC), Annals of oncology, 9, 1998, pp. 282-282
HIGH-INCIDENCE OF BRAIN METASTASES IN PATIENTS TREATED WITH AN M-VAC REGIMEN FOR ADVANCED BLADDER-CANCER
Authors: DHOTE R BEUZEBOC P THIOUNN N FLAM T ZERBIB M CHRISTOFOROV B DEBRE B
Citation: R. Dhote et al., HIGH-INCIDENCE OF BRAIN METASTASES IN PATIENTS TREATED WITH AN M-VAC REGIMEN FOR ADVANCED BLADDER-CANCER, European urology, 33(4), 1998, pp. 392-395
SURGERY OF LUNG METASTASES OF BREAST-CANCER - ANALYSIS OF 40 CASES
Authors: LIVARTOWSKI A CHAPELIER A BEUZEBOC P DIERICK A ASSELAIN B DARTEVELLE P POUILLART P
Citation: A. Livartowski et al., SURGERY OF LUNG METASTASES OF BREAST-CANCER - ANALYSIS OF 40 CASES, Bulletin du cancer, 85(9), 1998, pp. 799-802
UROTHELIAL BLADDER CANCERS
Authors: ANDRE F SORIA JC BEUZEBOC P HOUSSET M
Citation: F. Andre et al., UROTHELIAL BLADDER CANCERS, Bulletin du cancer, 1998, pp. 16-25
RANDOMIZED TRIAL COMPARING PROTRACTED INFUSION OF 5-FLUOROURACIL WITHWEEKLY DOXORUBICIN AND CYCLOPHOSPHAMIDE WITH A MONTHLY BOLUS FAC REGIMEN IN METASTATIC BREAST-CARCINOMA (SPM90)
Authors: PIERGA JY JOUVE M ASSELAIN B LIVARTOWSKI A BEUZEBOC P DIERAS V SCHOLL S DORVAL T PALANGIE T GARCIAGIRALT E POUILLART P
Citation: Jy. Pierga et al., RANDOMIZED TRIAL COMPARING PROTRACTED INFUSION OF 5-FLUOROURACIL WITHWEEKLY DOXORUBICIN AND CYCLOPHOSPHAMIDE WITH A MONTHLY BOLUS FAC REGIMEN IN METASTATIC BREAST-CARCINOMA (SPM90), British Journal of Cancer, 77(9), 1998, pp. 1474-1479
PARANEOPLASTIC PALMAR FASCIITIS AND ACHALASIA-LIKE ESOPHAGEAL DISORDER IN A PATIENT WITH BREAST-CANCER
Authors: DHOTE R BEUZEBOC P PERMAL S POIRAUDEAU S REVEL M CHRISTOFOROV B
Citation: R. Dhote et al., PARANEOPLASTIC PALMAR FASCIITIS AND ACHALASIA-LIKE ESOPHAGEAL DISORDER IN A PATIENT WITH BREAST-CANCER, Revue du rhumatisme, 64(5), 1997, pp. 350-352
OVEREXPRESSION OF PDGF RECEPTOR-BETA IN DERMAL FIBROBLASTS OF LYMPHANGITIC POST RADIOTHERAPY RELAPSES OF BREAST-CARCINOMA
Authors: PIERGA JY BENYAHIA B CAMMILLERI S PALANGIE T BEUZEBOC P POUILLART P MAGDELENAT H
Citation: Jy. Pierga et al., OVEREXPRESSION OF PDGF RECEPTOR-BETA IN DERMAL FIBROBLASTS OF LYMPHANGITIC POST RADIOTHERAPY RELAPSES OF BREAST-CARCINOMA, Breast, 6(4), 1997, pp. 206-211
PREDICTIVE AND PROGNOSTIC FACTORS - CLINICAL RELEVANCE
Authors: SCHOLL S BEUZEBOC P POUILLART P
Citation: S. Scholl et al., PREDICTIVE AND PROGNOSTIC FACTORS - CLINICAL RELEVANCE, European journal of cancer, 33, 1997, pp. 592-592
RESPONSE TO CHEMOTHERAPY IS THE FIRST PROGNOSTIC FACTOR IN METASTATICBREAST-CANCER
Authors: PIERGA JY JOUVE M ASSELAIN B DIERAS V BEUZEBOC P PALANGIE T DORVAL T GARCIAGIRALT E SCHOLL S POUILLART P
Citation: Jy. Pierga et al., RESPONSE TO CHEMOTHERAPY IS THE FIRST PROGNOSTIC FACTOR IN METASTATICBREAST-CANCER, European journal of cancer, 33, 1997, pp. 653-653
NONSEMINOMATOUS GERM-CELL TUMOR OF THE TE STICLE AND PULMONARY LANGERHANS HISTIOCYTOSIS - A FORTUITOUS ASSOCIATION
Authors: DEPINIEUX G DULMET E CHAPELIER A BEUZEBOC P DEBRE B
Citation: G. Depinieux et al., NONSEMINOMATOUS GERM-CELL TUMOR OF THE TE STICLE AND PULMONARY LANGERHANS HISTIOCYTOSIS - A FORTUITOUS ASSOCIATION, La Presse medicale, 26(3), 1997, pp. 118-119
SYSTEMIC LUPUS-ERYTHEMATOSUS PARANEOPLASTIC-SYNDROME
Authors: BLANCHE P ALKAIED F BEUZEBOC P NGUYEN B VINCENS AL GALEZOWSKI N CORVOL JC SICARD D
Citation: P. Blanche et al., SYSTEMIC LUPUS-ERYTHEMATOSUS PARANEOPLASTIC-SYNDROME, Clinical and experimental rheumatology, 15(5), 1997, pp. 581-582
IL-6 IS A SURVIVAL PROGNOSTIC FACTOR IN RENAL-CELL CARCINOMA
Authors: THIOUNN N PAGES F FLAM T TARTOUR E MOSSERI V ZERBIB M BEUZEBOC P DENEUX L FRIDMAN WH DEBRE B
Citation: N. Thiounn et al., IL-6 IS A SURVIVAL PROGNOSTIC FACTOR IN RENAL-CELL CARCINOMA, Immunology letters, 58(2), 1997, pp. 121-124
PHASE-II TRIAL OF DOXORUBICIN, 5-FLUOROURACIL, ETOPOSIDE, AND CISPLATIN IN ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA
Authors: PIERGA JY DIERAS V BEUZEBOC P DORVAL T PALANGIE T JOUVE M SCHOLL SM GARCIAGIRALT E POUILLART P
Citation: Jy. Pierga et al., PHASE-II TRIAL OF DOXORUBICIN, 5-FLUOROURACIL, ETOPOSIDE, AND CISPLATIN IN ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA, Gynecologic oncology, 66(2), 1997, pp. 246-249
MANAGEMENT OF MALIGNANT-TUMOR SPREAD - FROM BIOLOGY TO THERAPY
Authors: SCHOLL S BEUZEBOC P POUILLART P
Citation: S. Scholl et al., MANAGEMENT OF MALIGNANT-TUMOR SPREAD - FROM BIOLOGY TO THERAPY, Bulletin du cancer, 84(4), 1997, pp. 439-442
PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) IS NOT RELATED TO RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN BREAST-CANCER
Authors: PIERGA JY LAINEBIDRON C BEUZEBOC P DECREMOUX P POUILLART P MAGDELENAT H
Citation: Jy. Pierga et al., PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) IS NOT RELATED TO RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN BREAST-CANCER, British Journal of Cancer, 76(4), 1997, pp. 537-540
BRCA1 SEQUENCE VARIATIONS IN 160 INDIVIDUALS REFERRED TO A BREAST OVARIAN FAMILY CANCER CLINIC/
Authors: STOPPALYONNET D LAURENTPUIG P ESSIOUX L PAGES S ITHIER G LIGOT L FOURQUET A SALMON RJ CLOUGH KB POUILLART P ALAPETITE C ALEPEE B KLIJANIENKO J ASSELAIN B BEUZEBOC P BOURGEOIS D BOURGEOIS H BOURSTYN E BRUNIN F CAMPANA F CHAUVEINC F COSSET JM DECREMOUX P DELAROCHEFORDIERE A DELATTRE C DEMARGERIE V DESTGAUDENS AB DIERAS V DORVAL T DUBRAY B DURAND JC FALCOU MC FITOUSSI F GARCIAGIRALT E GIRAUD P GAUTIER C GUGLIELMINA JN HAMELIN JP HOFFMAN H JAULERRY C JOUVE M LABETA C LEGALL M MAGDELENAT H MEUNIER M MOSSERI V NGUYEN TT NATALI JC NEUENSCHWANDER S NOS C OLIVIER L PALANGIE T PIERGA JY PONTVERT D ROGE P SASTREGAREAU X SCHLIENGER P SCHOLL S SELINGER R THIBAULT F THIS P TROPHILME D VALIDIRE P VIELH P VILCOQ JR VINCENTSALOMON A VOILLEMOT N ZAFRANI B BONAITIPELLIE C THOMAS G
Citation: D. Stoppalyonnet et al., BRCA1 SEQUENCE VARIATIONS IN 160 INDIVIDUALS REFERRED TO A BREAST OVARIAN FAMILY CANCER CLINIC/, American journal of human genetics, 60(5), 1997, pp. 1021-1030
SEVERE 5-FLUOROURACIL TOXICITY POSSIBLY SECONDARY TO DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY IN A BREAST-CANCER PATIENT WITH OSTEOGENESIS IMPERFECTA
Authors: BEUZEBOC P PIERGA JY LYONNET DS ETIENNE MC MILANO G POUILLART P
Citation: P. Beuzeboc et al., SEVERE 5-FLUOROURACIL TOXICITY POSSIBLY SECONDARY TO DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY IN A BREAST-CANCER PATIENT WITH OSTEOGENESIS IMPERFECTA, European journal of cancer, 32A(2), 1996, pp. 369-370
PROTRACTED CONTINUOUS-INFUSION OF 5-FLUOROURACIL IN COMBINATION WITH DOXORUBICIN, VINCRISTINE, AND ORAL CYCLOPHOSPHAMIDE IN ADVANCED BREAST-CANCER
Authors: RAYMOND E PALANGIE T JOUVE M ASSELAIN B DIERAS V BEUZEBOC P DORVAL T GARCIAGIRALT E LIVARTOWSKI A SCHOLL S POUILLART P
Citation: E. Raymond et al., PROTRACTED CONTINUOUS-INFUSION OF 5-FLUOROURACIL IN COMBINATION WITH DOXORUBICIN, VINCRISTINE, AND ORAL CYCLOPHOSPHAMIDE IN ADVANCED BREAST-CANCER, Cancer investigation, 14(2), 1996, pp. 91-97
PHASE-II TRIAL OF DECAPEPTYL (D-TRP-6), A POTENT LUTEINIZING-HORMONE-RELEASING HORMONE ANALOG IN UNTREATED ADVANCED BREAST-CANCER
Authors: GARCIAGIRALT E BEUZEBOC P DIERAS V DORVAL T JOUVE M LIVARTOWSKI A PALANGIE T SCHOLL S POUILLART P
Citation: E. Garciagiralt et al., PHASE-II TRIAL OF DECAPEPTYL (D-TRP-6), A POTENT LUTEINIZING-HORMONE-RELEASING HORMONE ANALOG IN UNTREATED ADVANCED BREAST-CANCER, American journal of clinical oncology, 19(5), 1996, pp. 455-458
TREATMENT OF ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA WITH COMBINATION OF ETOPOSIDE, CISPLATIN, AND 5-FLUOROURACIL - A PHASE-II STUDY
Authors: PIERGA JY DIERAS V PARAISO D DORVAL T PALANGIE T BEUZEBOC P JOUVE M SCHOLL SM GARCIAGIRALT E POUILLART P
Citation: Jy. Pierga et al., TREATMENT OF ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA WITH COMBINATION OF ETOPOSIDE, CISPLATIN, AND 5-FLUOROURACIL - A PHASE-II STUDY, Gynecologic oncology, 60(1), 1996, pp. 59-63
Risultati: 1-25 | 26-45